How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative

Abstract

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application

“…According to the international consensus on ANA patterns (ICAP) [ 18 ], a low titer centromere pattern (AC-3) is to be confirmed by an antigen-specific immuno-assay for anti-CENP-B [ 19 ]. This indicates that, together with the pattern, the titer should be part of the report of the HEp-2 IIFA result [ 20 ]. However, the centromere pattern is most often associated with a high titer [ 21 , 22 ].…”

Prevalence of antinuclear antibodies in apparently healthy residents of the Hospital de Clínicas, San Lorenzo

“…Su importancia radica en que se debe conocer el perfil inmunológico de la población y aprender a contextualizar su uso en el estudio de patologías que conlleven autoinmunidad. Se recomienda el uso de la inmunofluorescencia indirecta en células HEp-2 como método estándar y la interpretación debe llevarse a cabo de forma sistematizada como se describe en las últimas guías sobre el consenso internacional de interpretación del ANA (ICAP) y los laboratorios que lleven a cabo este estudio deben adaptarse a estas guías para poder unificar los (22) criterios entre profesionales de la salud .…”

Rational development and application of biomarkers in the field of autoimmunity: A conceptual framework guiding clinicians and researchers

“…Another issue which might appear in the post-analytical phase is unclear reporting. To address this issue, the ICAP has published an international consensus towards harmonization [ 14 , 32 ] . Laboratories are requested to state the type of assay used (e.g.…”